Skip to main content

Table 2 Characteristics and resistance profiles of presumptive MDR-TB patients, MDR-TB surveillance programme, Madagascar, 2012–2017

From: Multidrug-resistant tuberculosis surveillance and cascade of care in Madagascar: a five-year (2012–2017) retrospective study

 201220132014201520162017Total
n (%)n (%)n (%)n (%)n (%)n (%)n (%)
Total202684884695366102391
Gender
 Male12 (60.0)195 (73.3)326 (66.9)302 (65.4)359 (67.0)426 (70.0)1620 (68.1)
 Female8 (40.0)71 (26.7)161 (33.1)160 (34.6)177 (33.0)183 (30.0)760 (31.9)
Median age (in years ± SD)45 ± 16.440 ± 13.240 ± 13.339 ± 14.440 ± 14.241 ± 14.740 ± 14.1
Previous treatment history
 Relapse4 (20.0)107 (39.9)257 (52.7)302 (64.4)376 (70.2)430 (70.5)1476 (61.7)
 Failure8 (40.0)69 (25.8)82 (16.8)58 (12.4)43 (8.0)73 (12.0)333 (13.9)
 Retreatment0 (0.0)21 (7.8)53 (10.9)54 (11.5)54 (10.1)61 (10.0)243 (10.2)
 Unknown8 (40.0)71 (26.5)96 (19.7)55 (11.7)63 (11.8)46 (7.5)339 (14.2)
Clinical form
 Pulmonary20 (100.0)249 (93.6)482 (98.8)452 (96.6)526 (98.1)580 (95.2)2309 (96.7)
 Extrapulmonary0 (0.0)17 (6.4)6 (1.2)16 (3.4)10 (1.9)29 (4.8)78 (3.3)
MTBC identification
 MTBC16 (84.2)229 (85.5)440 (90.2)367 (78.6)438 (81.7)478 (78.4)1968 (82.4)
 Non-MTBC3 (15.8)39 (14.5)48 (9.8)100 (21.4)98 (18.3)132 (21.6)420 (17.6)
Drug resistance profiles
 Pan-susceptible9 (56.3)199 (86.9)392 (89.1)331 (90.2)368 (84.0)427 (89.3)1726 (87.7)
 Isoniazid monoresistance3 (18.8)11 (4.8)24 (5.5)14 (3.8)38 (8.7)23 (4.8)113 (5.7)
 Rifampicin monoresistance0 (0.0)3 (1.3)6 (1.4)4 (1.1)7 (1.6)6 (1.3)26 (1.3)
 MDR-TB3 (18.8)13 (5.7)17 (3.9)16 (4.4)19 (4.3)21 (4.4)89 (4.5)
 Pre-XDR-TB0 (0.0)1 (0.4)1 (0.2)1 (0.3)0 (0.0)0 (0.0)3 (0.2)
 XDR-TB0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Other11 (0.1)2 (0.1)0 (0.0)1 (0.1)6 (0.3)1 (0.1)11 (0.5)
  1. Data missing for gender (n = 11), clinical form (n = 4) and MTBC identification (n = 3)
  2. MTBC Mycobacterium tuberculosis complex, MDR-TB multidrug-resistant tuberculosis, XDR-TB extensive drug-resistant tuberculosis, SD standard deviation
  3. 1Resistances to other drugs tested: aminoglycosides, ethambutol, ofloxacin, streptomycin
\